Zydus Wellness (531335) Q2 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 25/26 earnings summary
6 Nov, 2025Executive summary
Early and extended monsoons and GST 2.0 transition impacted sales in key seasonal categories, but non-seasonal and core brands showed resilience and maintained momentum.
Quick commerce and e-commerce channels continued strong growth, with tier 2 and 3 cities emerging as new growth drivers.
International expansion and digital business growth continued, with recent acquisitions (Comfort Click Limited and Naturell India Pvt. Ltd.) performing in line with expectations.
New product launches included Nutralite Activ Peanut Butter and RiteBite Millet Wafer Protein Bar, targeting health-conscious consumers.
Unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, were approved by the Board and certified by auditors with no material misstatements.
Financial highlights
Consolidated net sales grew 31% for the quarter and 12.8% for H1 FY26, driven by newly acquired entities and strong core brand performance.
Q2 FY26 net sales: ₹6,429 million (up 31% YoY); H1 FY26 net sales: ₹15,006 million (up 12.8% YoY).
Consolidated EBITDA reached INR 230 million, up 17.3% year-over-year.
Net loss including exceptional items and non-cash amortization was INR 528 million; adjusted net loss excluding exceptional items was INR 186 million.
Gross contribution margin improved to 52.4% in Q2 FY26 (+483 bps YoY); H1 FY26 at 53.7% (+118 bps YoY).
Outlook and guidance
Structural growth drivers remain intact despite temporary seasonal headwinds and GST 2.0 transition.
Management remains committed to achieving 17-18% EBITDA margin over the next two years through gross margin improvements and operating leverage.
Double-digit growth targeted over the next 3-5 years, leveraging multi-category, multi-channel, and multi-geography strategies.
Continued focus on innovation, digital engagement, and international expansion to drive future growth.
Revenues and profits are typically higher in the first and last quarters due to seasonality in product demand; current quarter performance may not be indicative of future quarters.
Latest events from Zydus Wellness
- Q3 FY26 revenue surged, but net loss continued due to acquisition and exceptional costs.531335
Q3 25/263 Feb 2026 - Q1 FY25 delivered 20% sales growth, margin expansion, and a debt-free balance sheet.531335
Q1 24/252 Feb 2026 - Double-digit sales growth, margin gains, and a major acquisition boost future prospects.531335
Q2 24/2515 Jan 2026 - Double-digit sales and profit growth, margin gains, and new product launches drove Q3 FY25.531335
Q3 24/259 Jan 2026 - Double-digit growth, margin gains, and digital expansion mark FY25, with major acquisition and dividend.531335
Q4 24/2520 Nov 2025 - Q1 FY26 saw 2.2% sales growth, resilient margins, and strong digital and acquisition-led gains.531335
Q1 25/2616 Nov 2025